Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Express Scripts
Merck
Harvard Business School
Mallinckrodt

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,183,226

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,183,226 protect, and when does it expire?

Patent 8,183,226 protects LEXISCAN and is included in one NDA.

This patent has twelve patent family members in twelve countries.

Summary for Patent: 8,183,226
Title:Myocardial perfusion imaging method
Abstract: The present disclosure provides 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A.sub.2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds in a variety of applications including myocardial perfusion imaging and coronary vasodilation methods. ##STR00001##
Inventor(s): Belardinelli; Luiz (Menlo Park, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/695,096
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,183,226

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes   Start Trial   Start Trial METHOD OF MYOCARDIAL IMAGING   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,183,226

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003259264   Start Trial
Canada 2492855   Start Trial
China 1671399   Start Trial
European Patent Office 1524984   Start Trial
Israel 166555   Start Trial
Japan 2005538190   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Baxter
McKesson
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.